哌拉西林/他唑巴坦治疗细菌感染的临床评价

评价哌拉西林/他唑巴坦治疗急性细菌性感染的安全性和有效性。方法131例患者随机分为哌拉西林/他唑巴坦组67例和特美汀组64例。哌拉西林/他唑巴坦组每日8～12g，疗程7～14d；特美汀组每日9.6～12.8g，疗程7～14d。结果哌拉西林/他唑巴坦和特美汀治疗组细菌感染痊愈率为62.7％和60.9％，有效率为89.6％和84.4％，细菌清除率为91.5％和89.1％，两组不良反应发生率为11.9％和6.25％，两组比较差异无显著性。结论哌拉西林/他唑巴坦是一种安全有效的抗感染药物。

CLINICAL EVALUATION OF PIPERACILLIN-TAZOBACTAM TREATMENT IN ACUTE BACTERIAL INFECTION

To evaluate clinical efficacy and safety of piperacillin-tazobactam treatment in acute bacterial infections. Methods: In this study 131 patients were randomized to receive either piperacillintazobactam 8～12g/d or ticarcillin-clavulanate 9.6～12.8g/d for 7～14 days. Sixty seven patients received pip eracillin-tazobactam and 64 patients received ticarcillin-clavnlanate. Results: The cure rates in piperacillin tazobactom and ticarcillin-clavulanate groups were 62.7 % and 60.9 % respectively and the efficary rates 89.6% and 84.4% respectively. Bacterial eradication rates were 91.5 % and 89.1% respectively. The side-effect rates were 11.9% and 6.25% respectively. There were no significant differences between two groups. Conclusion: Piperacillin-tazobactam is a kind of safe and effective anti-infection medicine.